IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Tempus Partners with JW Pharmaceutical to Leverage Real-World Data and Biological Modeling for Enhanced R&D

Devyser Secures NMPA Approval for Devyser Compact, Expanding Genetic Testing Market in China

Qure.ai Partners with Roche’s Startup Creasphere to Enhance Healthcare Innovation in APAC

Six NHS Trusts to Deploy deepc’s AI Radiology Platform in Partnership with AI4VBC

Precision Medicine Program Marks Major Advancement in Kidney Transplant Care for Hereditary Kidney Disease Patients

Helio Genomics and Halub Medical Announce Partnership to Launch HelioLiver Dx in GCC and Middle East

Merck's KEYTRUDA® (pembrolizumab) Secures 30th European Commission Approval with Two New Indications for Gynecologic Cancers

Dyno Therapeutics Expands Collaboration with Roche to Develop Next-Generation Gene Therapies for Neurological Diseases

Philips and Medtronic Partner to Advance Stroke Care and Awareness

Qatar Precision Health Institute Unveils Genomic Data and Announces New Research Initiatives

Caris Life Sciences Partners with ECOG-ACRIN to Advance Precision Medicine in Breast Cancer Research

Celemics and Strand Life Sciences Strengthen Partnership for Enhanced NGS Analysis

Thermo Fisher Partners with Telangana Government to Launch Bioprocess Design Centre in Hyderabad

Home
/
update
/
details

Gulf Scientific Corporation (GSC) Partners with SOPHiA GENETICS to Advance Precision Medicine in the GCC

NextEdge Admin

22 Oct 2024

2 min 14 sec

Gulf Scientific Corporation,artificial intelligence

Gulf Scientific Corporation (GSC), a leading provider of laboratory solutions in the Gulf Cooperation Council (GCC), has announced a strategic partnership with SOPHiA GENETICS, a global leader in data-driven medicine based in Switzerland. GSC will now represent SOPHiA GENETICS in the UAE, Saudi Arabia, Oman, Qatar, and Bahrain, delivering cutting-edge healthcare technologies across the region.

This collaboration strengthens GSC’s Life Science portfolio by integrating SOPHiA GENETICS’ advanced solutions, designed to drive precision medicine. SOPHiA GENETICS harnesses artificial intelligence (AI) for multimodal analysis, combining data from multiple sources to generate actionable insights. These solutions empower healthcare providers to make data-driven decisions that enhance diagnosis, treatment, and patient care.

GSC will offer SOPHiA GENETICS' innovative technologies to tackle complex challenges in key medical areas such as Oncology, Rare and Inherited Diseases, and Real-World Data. SOPHiA’s AI-powered platforms enable the detection of specific mutations and biomarkers critical for personalized treatment planning, facilitating improved clinical outcomes and more effective care strategies.

SOPHiA GENETICS’ solutions are widely adopted by healthcare professionals worldwide to monitor and research cancer, providing crucial insights that support precision medicine.
SOPHiA GENETICS is a cloud-native healthcare technology company committed to expanding access to data-driven medicine globally. Its flagship SOPHiA DDM™ Platform analyzes complex genomic and multimodal data, delivering real-time insights to hospitals, laboratories, and biopharma organizations, advancing personalized care for cancer and rare disease patients.